Acera Surgical, Inc.
$863.7K 4,195 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
L&k Biomed Co. , Ltd.
L&k Biomed Co. , Ltd. reported $864,759.20 across General Payments, Research, and Ownership to 38 physicians and teaching hospitals across 38 transactions.
- $864.8K Above-median payer
- All-tracks total
- 38 Below-median volume
- Transactions
- 38 Below-median reach
- Recipients
- +$811.9K
- General Payments vs PY2023
L&k Biomed Co. , Ltd. reported $864,759.20 across all CMS Open Payments tracks (General + Research + Ownership) to 38 physicians and teaching hospitals in Program Year 2024 - ranking #651 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $864,759.20, averaging $22.8K per recipient.
L&k Biomed Co. , Ltd.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
19/100
Total payments
F
18/100
Transaction volume
F
10/100
Physician reach
F
10/100
Payment type diversity
F
37/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer l-k-biomed-co-ltd L&k Biomed Co. , Ltd.
$864.8K · #651/1,925 · 0.0% industry · PY2024
- TOT $864.8K
- RANK #651
- SHARE 0.0%
- TXN 38
- RCP 38
- CAT 3
- GEN $864.8K
- ΔGEN +$811.9K
- TOP1 43.4%
- PY 2024
Volume peers
Nearest volume peer: Acera Surgical, Inc. ($863.7K)
L&k Biomed Co. , Ltd. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
L&k Biomed Co. , Ltd.'s CMS-reported General Payments increased by $811.9K (+1534.5%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: L&K BIOMED CO. , LTD.PY2023: L&K BIOMED CO. , LTD.PY2024: L&K BIOMED CO. , LTD.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $52,906.38
- PY2024
- $864,759.20
What the Data Shows for L&k Biomed Co. , Ltd.
CMS Open Payments is not a single ledger: the all-tracks total shown above is General Payments plus Research Payments plus Ownership/Investment interests, each with its own disclosure rules. For L&k Biomed Co. , Ltd. that figure is drawn almost entirely from the General Payments track (day-to-day consulting, meals, travel and speaking fees). Data for a given Program Year arrives roughly a year after the period it covers; our methodology page documents the release cadence and how we standardize the tracks for cross-company comparison.
"Royalty or License" leads the 3-category general-payment breakdown below at $467.6K (54.1% of General Payments, 12 transactions) - see our methodology for how research and ownership payments are reported separately.
General Payment Breakdown by Type
Across 3 types of general payments, L&k Biomed Co. , Ltd.'s largest category was "Royalty or License" at $467.6K - 54.1% of General Payments.
How L&k Biomed Co. , Ltd. divides its payments
Ranked by total dollars reported per category
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Royalty or License | $467.6K | 12 | 54.1% |
| Consulting Fee | $385.1K | 25 | 44.5% |
| Travel and Lodging | $12.1K | 1 | 1.4% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $864,759.20 (100.0%) of $864,759.20 in this company's General Payments records across 5 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for L&k Biomed Co. , Ltd.
The five named recipients with the highest reported General Payments from this company
- 1
Anthony Sin
$375,500.00 across 24 reported transactions
- 2
Fernando Villamil
$250,500.00 across 2 reported transactions
- 3
Gary Fleischer
$217,100.00 across 10 reported transactions
- 4
Saqib Hasan
$12,059.20 across 1 reported transactions
- 5
Jayant Jagannathan
$9,600.00 across 1 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
L&k Biomed Co. , Ltd.'s spend rank (#651 of 1,925, top 34% by spend) and concentration rank (#522 of 1,838, top 28% most concentrated) land at roughly the same percentile, an unusually proportionate case where payment size and payment concentration move together.
View all 12 companies in this HHI neighborhood as a list
- Biocircuit Technologies Inc : $69.8K total payments, HHI 3424
- Organ Recovery Systems, Inc. : $356.7K total payments, HHI 3422
- Omniscient Neurotechnology America Ltd : $73.2K total payments, HHI 3397
- FlexDex Inc. : $350.51 total payments, HHI 3376
- Seres Therapeutics, Inc. : $132.4K total payments, HHI 3375
- Orthopedic Sciences, Inc. : $4.0K total payments, HHI 3369
- L&k Biomed Co. , Ltd. (this company) : $864.8K total payments, HHI 3358
- Nidek Incorporated : $16.8K total payments, HHI 3356
- Grifols Diagnostic Solutions, Inc. : $48.20 total payments, HHI 3353
- Roche Diabetes Care GmbH : $52.4K total payments, HHI 3353
- OrganOx Ltd : $271.0K total payments, HHI 3335
- Midwest Surgical Alliance, LLC : $994.3K total payments, HHI 3333
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as L&k Biomed Co. , Ltd.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about L&k Biomed Co. , Ltd..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with L&k Biomed Co. , Ltd..
Showing 6 of 1,924 companies with CMS-reported payment data.
Sanara MedTech Inc.
$866.5K 2,677 recipients
Compare payment profiles
Life Technologies Corporation
$868.1K 479 recipients
Compare payment profiles
Jenavalve Technology, Inc.
$869.0K 185 recipients
Compare payment profiles
Cornerstone Specialty Network LLC
$855.8K 79 recipients
Compare payment profiles
Adagio Medical, Inc.
$855.0K 19 recipients
Compare payment profiles
Put this to use
L&k Biomed Co. , Ltd. ranks #651 of 1,925 by all-tracks total payments, led by "Royalty or License".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Royalty or License" spend across every manufacturer, not just L&k Biomed Co. , Ltd.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.